Formation Bio
Formation Bio is a tech-driven pharmaceutical company using proprietary AI platforms to optimize and accelerate clinical drug development.
Secondary Market Price
How Formation Bio Measures Up
To help you manage your Formation Bio equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Formation Bio's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Formation Bio Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Formation Bio's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Formation Bio is a technology-driven pharmaceutical company that acquires clinical-stage drugs and uses proprietary artificial intelligence platforms to manage their development. The company's current activities focus on optimizing aspects of clinical trials, including their design, completion speed, and the quality of the data collected. An example of its work is the development of LNK01006, a TYK2 inhibitor, which is being advanced through its subsidiary, Bleecker Bio. Founded in 2013 and previously known as Trialspark, the company was established by Benjamine Liu, who serves as CEO, and Linhao Zhang, the COO.
Looking forward, Formation Bio plans to continue acquiring clinical-stage assets and expanding its development pipeline. A Phase 1 study for LNK01006 is scheduled for the first half of 2026. The company has recently made several announcements, including the closing of a $372 million Series D funding round in July 2024 and the opening of a new office in Boston. It also launched ARK, a platform designed to connect data and AI tools across the organization. In 2024 and 2025, the company received recognition through several industry awards, including the 2025 CNBC Disruptor 50, the 2025 Fierce 15 Award, and the 2024 Endpoints 11 Award.
- Andreessen Horowitz
- Sanofi
- Sequoia Capital
- Thrive Capital
- Emerson Collective
- Lachy Groom
- SV Angel Growth
- FPV Ventures
- Sam Altman
- Michael Moritz
- John Doerr
- Section 32
- Casdin Capital
- Felicis
- Spark Capital
- Co-Founder, Benjamine Liu
- Co-Founder, Linhao Zhang
- Co-Founder, Kit Dobyns
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Formation Bio worth joining?
Deciding whether to join a company like Formation Bio depends on your personal career goals and financial situation. Tools like Prospect can help you analyze the potential value of your equity compensation to make a more informed decision.
What should I do with my Formation Bio stock?
Managing stock in a private company like Formation Bio requires careful planning around taxes and timing. Platforms such as Prospect offer customized strategies for exercising options and selling shares to help you maximize your potential returns.
Can you sell Formation Bio stock?
Selling stock in a private company like Formation Bio is typically possible during specific liquidity events, such as tender offers or on secondary markets. Tools like Prospect's tender offer tools can help you navigate these opportunities and decide how much to sell for optimal tax outcomes.
How can I find the value of my Formation Bio stock?
Valuing stock in a private company is challenging because it isn't traded on a public exchange and its price isn't readily available. Prospect uses predictive models trained on venture capital data to help you forecast the potential future value of your Formation Bio shares.
What is Formation Bio's equity worth?
The precise worth of your Formation Bio equity depends on the company's valuation, your number of shares, and your tax situation. You can use a platform like Prospect to upload your equity details and receive personalized projections on your potential post-tax equity value.
What is Formation Bio's stock ticker symbol?
As a private company, Formation Bio does not have a stock ticker symbol because it is not listed on a public stock exchange. Ticker symbols are only assigned to companies when they undergo an Initial Public Offering (IPO).
Can I buy or sell Formation Bio stock?
For employees, "buying" stock typically means exercising your stock options, while selling is possible during specific liquidity events like tender offers. The general public cannot typically buy or sell shares in a private company like Formation Bio until it goes public.
What is the criteria to buy or invest in Formation Bio stock?
Investing in a private company like Formation Bio is typically restricted to employees who receive stock as part of their compensation or to accredited investors in private funding rounds. It is generally not available for purchase by the general public on an open market.
